Brugger Wolfram
Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
Semin Oncol. 2004 Feb;31(1 Suppl 2):33-7.
Advanced follicular and mantle cell lymphoma are currently incurable using conventional chemotherapy. As such, new and potentially more effective therapeutic approaches such as high-dose chemotherapy with autologous stem cell transplantation (ASCT) and consolidation using various types of therapy are being increasingly considered. Rituximab has been assessed as an in vivo purge and as consolidation therapy both first-line and in relapsed patients with follicular and mantle cell lymphoma. Data from a number of studies are reviewed, focusing on our recently reported phase II study of patients with follicular or mantle cell lymphoma who received one standard course of rituximab consolidation therapy after ASCT to show that using rituximab in the context of high-dose chemotherapy and ASCT may improve patient outcomes without compromising tolerability. Specifically, purging and consolidation using rituximab can improve clinical and molecular response rates, may eliminate minimal residual disease, and may improve survival. These studies suggest that rituximab may have an important role in improving the outcome of ASCT in patients with follicular or mantle cell lymphoma.
晚期滤泡性和套细胞淋巴瘤目前使用传统化疗无法治愈。因此，越来越多地考虑采用新的、可能更有效的治疗方法，如大剂量化疗联合自体干细胞移植（ASCT）以及使用各种类型疗法进行巩固治疗。利妥昔单抗已被评估可作为体内净化以及一线和复发的滤泡性和套细胞淋巴瘤患者的巩固治疗。本文回顾了多项研究的数据，重点关注我们最近报道的一项II期研究，该研究针对接受ASCT后接受一个标准疗程利妥昔单抗巩固治疗的滤泡性或套细胞淋巴瘤患者，以表明在大剂量化疗和ASCT背景下使用利妥昔单抗可能改善患者预后而不影响耐受性。具体而言，使用利妥昔单抗进行净化和巩固可提高临床和分子缓解率，可能消除微小残留病，并可能改善生存率。这些研究表明，利妥昔单抗可能在改善滤泡性或套细胞淋巴瘤患者ASCT的预后方面发挥重要作用。
